Crossmark

Clinical Benefits of Tezepelumab in a Real-World Cohort of Patients With Severe Uncontrolled Asthma in Castilla-La Mancha, Spain

Crossref DOI link: https://doi.org/10.1016/j.opresp.2026.100617

Published Print: 2026-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Bujalance-Cabrera, Carlos

Espinosa de los Monteros-Garde, María José

Morena-Vallés, Diego

Godoy-Mayoral, Raúl

Bravo-Nieto, José Manuel

Jiménez-Arroyo, Marta

Jiménez-López, Jesús

Lázaro-Polo, Francisco Javier

Izquierdo-Alonso, José Luis
Funding

Funding for this research was provided by:

AstraZeneca España

AstraZeneca
License Information

Text and Data Mining valid from 2026-07-01

Text and Data Mining valid from 2026-07-01

Version of Record valid from 2026-03-24
More Information

This article is maintained by: Elsevier

Article Title: Clinical Benefits of Tezepelumab in a Real-World Cohort of Patients With Severe Uncontrolled Asthma in Castilla-La Mancha, Spain

Journal Title: Open Respiratory Archives

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.opresp.2026.100617

Content Type: article

Copyright: © 2026 Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Published by Elsevier España, S.L.U.